ARTHUR SYTKOWSKI

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Does erythropoietin have a dark side? Epo signaling and cancer cells
    Arthur J Sytkowski
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Sci STKE 2007:pe38. 2007
  2. ncbi Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells
    Jee Yeong Jeong
    Department of Medicine, Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Cancer 122:274-80. 2008
  3. ncbi Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype
    Peter Solar
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Int J Cancer 122:281-8. 2008
  4. ncbi Apoptosis-linked gene-2 connects the Raf-1 and ASK1 signalings
    Changmin Chen
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, USA
    Biochem Biophys Res Commun 333:51-7. 2005
  5. ncbi Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells
    Laurie Feldman
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Prostate 66:135-45. 2006
  6. ncbi An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells
    Jee Yeong Jeong
    Laboratory for Cell and Molecular Biology, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Mol Cancer Res 7:1150-7. 2009
  7. ncbi Variability in the immunodetection of His-tagged recombinant proteins
    Natasa Debeljak
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, 330 Brookline Ave, W/BL 548, Boston, MA 02215, USA
    Anal Biochem 359:216-23. 2006
  8. ncbi Measurement of hemoglobin in long-term fixed erythroid cells: application development for cell science experiments in microgravity
    Kun Xu
    Laboratory for Cellular and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Methods Cell Sci 25:247-52. 2003
  9. ncbi Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells
    Peter Solar
    Laboratory for Cell and Molecular Biology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Mol Cancer Ther 7:2263-71. 2008
  10. ncbi Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner
    Jee Yeong Jeong
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Biochem Biophys Res Commun 379:583-8. 2009

Research Grants

  1. Chemopreventive Action of Human Selenium Binding Protein
    ARTHUR SYTKOWSKI; Fiscal Year: 2002
  2. PROTEIN DIMERS AS CANCER THERAPEUTICS
    ARTHUR SYTKOWSKI; Fiscal Year: 2004

Collaborators

Detail Information

Publications13

  1. ncbi Does erythropoietin have a dark side? Epo signaling and cancer cells
    Arthur J Sytkowski
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Sci STKE 2007:pe38. 2007
    ..The unexpected results of several clinical studies in which Epo was used to treat cancer patients have now raised the question of a potential direct growth-promoting action of Epo on cancer cells...
  2. ncbi Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells
    Jee Yeong Jeong
    Department of Medicine, Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Int J Cancer 122:274-80. 2008
    ....
  3. ncbi Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype
    Peter Solar
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Int J Cancer 122:281-8. 2008
    ..These findings may have implications for the clinical use of recombinant human Epo and other erythropoiesis stimulating agents to correct anemia in paclitaxel-treated cancer patients...
  4. ncbi Apoptosis-linked gene-2 connects the Raf-1 and ASK1 signalings
    Changmin Chen
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, USA
    Biochem Biophys Res Commun 333:51-7. 2005
    ..Since ALG-2 associates with ASK1, and both ASK1 and ALG-2 are involved in apoptosis, our observations indicate that Raf-1 may mediate its anti-apoptotic function by interrupting ASK1-dependent phosphorylation of ALG-2...
  5. ncbi Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells
    Laurie Feldman
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Prostate 66:135-45. 2006
    ..EpoR have been identified on a variety of non-hematopoietic cells, both normal and malignant, however, little is known about the function of EpoR on malignant cells...
  6. ncbi An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells
    Jee Yeong Jeong
    Laboratory for Cell and Molecular Biology, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA
    Mol Cancer Res 7:1150-7. 2009
    ..Taken together, our data suggest that the coordinated regulation of a functional erythropoietin/erythropoietin receptor axis in prostate cancer cells may be integral to the growth and progression of prostate cancer...
  7. ncbi Variability in the immunodetection of His-tagged recombinant proteins
    Natasa Debeljak
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, 330 Brookline Ave, W/BL 548, Boston, MA 02215, USA
    Anal Biochem 359:216-23. 2006
    ..Such variability in His-tag immunorecognition can lead to critical adverse effects on several analytical methods...
  8. ncbi Measurement of hemoglobin in long-term fixed erythroid cells: application development for cell science experiments in microgravity
    Kun Xu
    Laboratory for Cellular and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215, USA
    Methods Cell Sci 25:247-52. 2003
    ....
  9. ncbi Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells
    Peter Solar
    Laboratory for Cell and Molecular Biology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Mol Cancer Ther 7:2263-71. 2008
    ..These results may have important implications for ovarian cancer patients undergoing PDT and receiving erythropoietin...
  10. ncbi Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner
    Jee Yeong Jeong
    Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    Biochem Biophys Res Commun 379:583-8. 2009
    ..These findings suggest that hSP56 may play a role in ubiquitination/deubiquitination-mediated protein degradation pathways in a selenium-dependent manner...
  11. ncbi Erythropoietin regulation of Raf-1 and MEK: evidence for a Ras-independent mechanism
    Changmin Chen
    Harvard Med Sch, Boston, MA
    Blood 104:73-80. 2004
    ..These results indicate the presence of a Ras-independent mechanism for Raf-1 and MEK activation in these cells...
  12. ncbi Erythropoietin and IL-3 receptor cell surface expression is decreased under conditions that model some aspects of microgravity
    Kun Xu
    Harvard Med Sch, Boston, MA
    Gravit Space Biol Bull 18:111-2. 2005
  13. ncbi The erythropoietin receptor in normal and cancer tissues
    Wolfgang Jelkmann
    Institute of Physiology, University of Luebeck, Ratzeburger Allee 160, D 23538 Luebeck, Germany
    Crit Rev Oncol Hematol 67:39-61. 2008
    ....

Research Grants5

  1. Chemopreventive Action of Human Selenium Binding Protein
    ARTHUR SYTKOWSKI; Fiscal Year: 2002
    ..This work will provide essential data leading to new ideas in prostate cancer biology and the role of selenium in cancer prevention. ..
  2. PROTEIN DIMERS AS CANCER THERAPEUTICS
    ARTHUR SYTKOWSKI; Fiscal Year: 2004
    ..The potential immunogenicity, structure and stability of these compounds will be studied. The results of these experiments will lay the foundation for the design of novel recombinant proteins for cancer therapy. ..